CELLSELECT

Significantly reduce the risk, time and cost associated with new target and drug discovery.

Leading Cancer Research

BerGenBio's lead development program, BGB324, the first-in-class oral AXL inhibitor will enter Phase 1 clinical trials in 2012.

News

View All News & Events

Events

Print